Figure 7. mTOR kinase inhibition-induced reactivation of AKT substrates and RTKs in vivo and can be blocked by addition of a HER kinase inhibitor.

(A) Mice bearing BT-474 tumors were treated with increasing doses of AZD8055 for four hours; the samples were immunoblotted with the indicated antibodies. (B) Mice bearing BT-474 tumors were treated with 75mg/kg of AZD8055 for the indicated times; the samples were immunoblotted with the indicated antibodies. (C) Mice bearing BT-474 tumors were randomized to vehicle, AZD8055 (75mg/kg) three times per week, lapatinib (150mg/kg), three times per week or the combination for three weeks. Tumor size was measured twice per week. The results are presented as the mean tumor volume ± SEM (n = 5 mice/group).